A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Inclusion Criteria: * Must be male or female and at least 18 years of age. * Female patients must be of: * Non-childbearing potential; * Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception. * 4 to 8 AK lesions on non-head locations. Exclusion Criteria: * Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area. * Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks. * Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area